Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| HCW Biologics Inc.HCWB · Entity 8172 | Director | May 07, 2025 | May 09, 2025 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
HCW Biologics Inc.
Report date May 07, 2025 · Filed May 09, 2025
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 2,066 |
Reported balance
After 2025-05-08 transaction · row 1
1 source rowRow 1 · 2025-05-08 · Purchase · Acquired 962 · Balance 2,066 F1: These shares are being issued as a portion of and pursuant to the Company entering into a definitive conversion agreement on May 1, 2025, with a conversion date of May 7, 2025, along with 13 other holders of $6.6 million of the outstanding principal of the Secured Notes to convert the Secured Notes for an aggregate of 253,083 shares of the Company's Common Stock at a conversion price of $26.00 per share (on a post-reverse split basis), issuance of an aggregate of 126,540 warrants each exercisable for one share of Common Stock at an exercise price of $26.00 per share (on a post-reverse split basis), and a portion of the 2,174,311 shares of Wugen Inc. common stock held by the Company. |
| Common Stock Purchase WarrantSEC Table II · derivative / convertible security · Conversion / exercise price $26.00 · Expires 2030-05-07 | Direct | 481 |
Reported balance
After 2025-05-07 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2025-05-07 · Purchase · Acquired 481 · Balance 481 F1: These shares are being issued as a portion of and pursuant to the Company entering into a definitive conversion agreement on May 1, 2025, with a conversion date of May 7, 2025, along with 13 other holders of $6.6 million of the outstanding principal of the Secured Notes to convert the Secured Notes for an aggregate of 253,083 shares of the Company's Common Stock at a conversion price of $26.00 per share (on a post-reverse split basis), issuance of an aggregate of 126,540 warrants each exercisable for one share of Common Stock at an exercise price of $26.00 per share (on a post-reverse split basis), and a portion of the 2,174,311 shares of Wugen Inc. common stock held by the Company. |
Filing footnotes · ownership attribution and instrument terms
F1: These shares are being issued as a portion of and pursuant to the Company entering into a definitive conversion agreement on May 1, 2025, with a conversion date of May 7, 2025, along with 13 other holders of $6.6 million of the outstanding principal of the Secured Notes to convert the Secured Notes for an aggregate of 253,083 shares of the Company's Common Stock at a conversion price of $26.00 per share (on a post-reverse split basis), issuance of an aggregate of 126,540 warrants each exercisable for one share of Common Stock at an exercise price of $26.00 per share (on a post-reverse split basis), and a portion of the 2,174,311 shares of Wugen Inc. common stock held by the Company.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| May 08, 2025 Filed May 9, 2025 17:28 UTC | HCW Biologics Inc. HCWB · Entity 8172 | PurchaseCommon Stock | 962 | $26.00 | $25,012.00 |
DisclosureSEC source: 0000950170-25-068271 · ownership.xml · nonDerivative · entry 1 Greene Rick S. · CIK 0001866272 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,066 F1 · kind: These shares are being issued as a portion of and pursuant to the Company entering into a definitive conversion agreement on May 1, 2025, with a conversion date of May 7, 2025, along with 13 other holders of $6.6 million of the outstanding principal of the Secured Notes to convert the Secured Notes for an aggregate of 253,083 shares of the Company's Common Stock at a conversion price of $26.00 per share (on a post-reverse split basis), issuance of an aggregate of 126,540 warrants each exercisable for one share of Common Stock at an exercise price of $26.00 per share (on a post-reverse split basis), and a portion of the 2,174,311 shares of Wugen Inc. common stock held by the Company. Read SEC document |
| May 07, 2025 Filed May 9, 2025 17:28 UTC | HCW Biologics Inc. HCWB · Entity 8172 | PurchaseCommon Stock Purchase Warrant · Derivative | 481 | $0.00 Strike: $26.00 | $0.00 |
DisclosureSEC source: 0000950170-25-068271 · ownership.xml · derivative · entry 2 Greene Rick S. · CIK 0001866272 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 481 Underlying: Common Stock · 481 shares Expires 2030-05-07 F1 · kind: These shares are being issued as a portion of and pursuant to the Company entering into a definitive conversion agreement on May 1, 2025, with a conversion date of May 7, 2025, along with 13 other holders of $6.6 million of the outstanding principal of the Secured Notes to convert the Secured Notes for an aggregate of 253,083 shares of the Company's Common Stock at a conversion price of $26.00 per share (on a post-reverse split basis), issuance of an aggregate of 126,540 warrants each exercisable for one share of Common Stock at an exercise price of $26.00 per share (on a post-reverse split basis), and a portion of the 2,174,311 shares of Wugen Inc. common stock held by the Company. Read SEC document |
| June 14, 2024 Filed Jun 17, 2024 16:57 UTC | HCW Biologics Inc. HCWB · Entity 8172 | GrantStock Option (Right to Buy) · Derivative | 12,500 | $0.00 Strike: $1.12 | $0.00 |
DisclosureSEC source: 0000950170-24-074333 · ownership.xml · derivative · entry 1 Greene Rick S. · CIK 0001866272 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 12,500 Underlying: Common Stock · 12,500 shares Expires 2034-06-13 F1 · derivative.exercise_date: (1) 100% of the total number of shares subject to the Option shall vest and become exercisable on the earlier of (a) June 13, 2025 or (b) the next annual meeting of stockholders, subject to the Reporting Person continuing to provide services through the vesting date. Read SEC document |
| February 20, 2024 Filed Feb 22, 2024 14:23 UTC | HCW Biologics Inc. HCWB · Entity 8172 | GrantCommon Stock | 35,714 | $1.40 | $49,999.60 |
DisclosureSEC source: 0001209191-24-003786 · doc4.xml · nonDerivative · entry 1 Greene Rick S. · CIK 0001866272 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 44,125 F1 · kind: The reporting person purchased these shares directly from the issuer in a private placement, which transaction is exempt from Section 16(b) in accordance with Rule 16b-3(d) promulgated under the Securities Exchange Act of 1934, as amended. Read SEC document |
| June 13, 2023 Filed Jun 15, 2023 17:14 UTC | HCW Biologics Inc. HCWB · Entity 8172 | GrantStock Option (Right to Buy) · Derivative | 12,500 | $0.00 Strike: $2.01 | $0.00 |
DisclosureSEC source: 0001209191-23-037424 · doc4.xml · derivative · entry 1 Greene Rick S. · CIK 0001866272 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 12,500 Underlying: Common Stock · 12,500 shares Expires 2033-06-12 F1 · derivative.exercise_date: 100% of the total number of shares subject to the Option shall vest and become exercisable on the earlier of (a) June 13, 2024 or (b) the next annual meeting of stockholders, subject to the Reporting Person continuing to provide services through the vesting date. Read SEC document |
| June 15, 2022 Filed Jun 17, 2022 16:20 UTC | HCW Biologics Inc. HCWB · Entity 8172 | GrantStock Option (Right to Buy) · Derivative | 41,841 | $0.00 Strike: $2.39 | $0.00 |
DisclosureSEC source: 0001209191-22-037853 · doc4.xml · derivative · entry 1 Greene Rick S. · CIK 0001866272 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 41,841 Underlying: Common Stock · 41,841 shares Expires 2032-06-14 F1 · derivative.exercise_date: 100% of the total number of shares subject to the Option shall vest and become exercisable on the earlier of (a) June 15, 2023 or (b) the next annual meeting of stockholders, subject to the Reporting Person continuing to provide services through the vesting date. Read SEC document |
| June 02, 2022 Filed Jun 6, 2022 16:16 UTC | HCW Biologics Inc. HCWB · Entity 8172 | PurchaseCommon Stock | 4,800 | $2.09 | $10,040.64 |
DisclosureSEC source: 0001209191-22-034510 · doc4.xml · nonDerivative · entry 1 Greene Rick S. · CIK 0001866272 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,411 F1 · price: The range of prices for the shares of Common Stock is from $2.02 to $2.10. The reporting person undertakes that he will provide, upon request by the staff of the U.S. Securities and Exchange Commission, full information regarding the number of securities purchased at each separate price. Read SEC document |
| August 25, 2021 Filed Aug 27, 2021 16:42 UTC | HCW Biologics Inc. HCWB · Entity 8172 | PurchaseCommon Stock | 3,611 | $4.10 | $14,821.35 |
DisclosureSEC source: 0001209191-21-053633 · doc4.xml · nonDerivative · entry 1 Greene Rick S. · CIK 0001866272 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,611 F1 · price: The range of prices for the shares of Common Stock is from $4.09 to $4.11. The reporting person undertakes that he will provide, upon request by the staff of the U.S. Securities and Exchange Commission, full information regarding the number of securities purchased at each separate price. Read SEC document |
| July 22, 2021 Filed Aug 27, 2021 16:42 UTC | HCW Biologics Inc. HCWB · Entity 8172 | GrantStock Option · Derivative | 20,964 | $0.00 Strike: $4.77 | $0.00 |
DisclosureSEC source: 0001209191-21-053633 · doc4.xml · derivative · entry 2 Greene Rick S. · CIK 0001866272 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,964 Underlying: Common Stock · 20,964 shares Expires 2031-07-21 F2 · derivative.exercise_date: The option will fully vest on July 22, 2022. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.